IL-12 as an adjuvant for the enhancement of protective humoral immunity

References

• Elson CO, Dertzbaugh MT. Mucosal adjuvants. In: Mucosal Immunology (3rd Edition). Mestecky J, Lamm ME, Strober W et al. (Eds). Elsevier Academic Press, Amsterdam, The Netherlands 967–986 (2005).
   Google Scholar
• Liang XP, Lamm ME, Nedrud JG. Cholera toxin as a mucosal adjuvant for respiratory antibody responses in mice. Reg. Immunol.2, 244–248 (1989).
   PubMedGoogle Scholar
• Wu HY, Russell MW. Induction of mucosal immunity by intranasal application of a streptococcal surface protein antigen with the cholera toxin B subunit. Infect. Immun.61, 314–322 (1993).
   PubMed Web of Science ®Google Scholar
• Couch RB. Nasal vaccination, Escherichia coli enterotoxin, and Bell’s Palsy. N. Engl. J. Med.350(9), 860–861 (2004).
   PubMed Web of Science ®Google Scholar
• Marinaro M, Staats HF, Hiroi T et al. Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4. J. Immunol.155(10), 4621–4629 (1995).
   PubMed Web of Science ®Google Scholar
• Braun MC, He J, Wu CY, Kelsall BL. Cholera toxin suppresses interleukin (IL)-12 production and IL-12 receptor β1 and β2 chain expression. J. Exp. Med.189(3), 541–552 (1999).
   PubMed Web of Science ®Google Scholar
• Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol.3(2), 133–146 (2003).
   PubMed Web of Science ®Google Scholar
• Brombacher F, Kastelein RA, Alber G. Novel IL-12 family members shed light on the orchestration of Th1 responses. Trends Immunol.24(4), 207–212 (2003).
   PubMed Web of Science ®Google Scholar
• Buchanan JM, Vogel LA, Van Cleave VH, Metzger DW. Interleukin 12 alters the isotype-restricted antibody response of mice to hen eggwhite lysozyme. Int. Immunol.7(9), 1519–1528 (1995).
   PubMed Web of Science ®Google Scholar
• Metzger DW, Buchanan JM, Collins JT et al. Enhancement of humoral immunity by interleukin-12. Ann. NY Acad. Sci.795, 100–115 (1996).
   PubMed Web of Science ®Google Scholar
• McKnight AJ, Zimmer GJ, Fogelman I, Wolf SF, Abbas AK. Effects of IL-12 on helper T cell-dependent immune responses in vivo. J. Immunol.152, 2172–2179 (1994).
   PubMed Web of Science ®Google Scholar
• Germann T, Bongartz M, Dlugonska H et al. Interleukin-12 profoundly up-regulates the synthesis of antigen-specific complement-fixing IgG2a, IgG2b, and IgG3 antibody subclasses in vivo. Eur. J. Immunol.25, 823–829 (1995).
   PubMed Web of Science ®Google Scholar
• Morris SC, Madden KB, Adamovicz JJ et al. Effects of IL-12 on in vivo cytokine gene expression and Ig isotype selection. J. Immunol.152, 1047–1056 (1994).
   PubMed Web of Science ®Google Scholar
• Bliss J, Van Cleave V, Murray K et al. IL-12, as an adjuvant, promotes a T helper 1 cell, but does not suppress a T helper 2 cell recall response. J. Immunol.156(3), 887–894 (1996).
   PubMed Web of Science ®Google Scholar
• Vogel LA, Showe LC, Lester TL et al. Direct binding of IL-12 to human and murine B lymphocytes. Int. Immunol.8(12), 1955–1962 (1996).
   PubMed Web of Science ®Google Scholar
• Jones D, Elloso MM, Showe L et al. Differential regulation of the interleukin-12 receptor during the innate immune response to Leishmania major. Infect. Immun.66(8), 3818–3824 (1998).
   PubMed Web of Science ®Google Scholar
• Airoldi I, Gri G, Marshall JD et al. Expression and function of IL-12 and IL-18 receptors on human tonsillar B cells. J. Immunol.165(12), 6880–6888 (2000).
   PubMed Web of Science ®Google Scholar
• Jelinek DF, Braaten JK. Role of IL-12 in human B lymphocyte proliferation and differentiation. J. Immunol.154, 1606–1613 (1995).
   PubMed Web of Science ®Google Scholar
• Yoshimoto T, Okamura H, Tagawa Y-I, Iwakura Y, Nakanishi K. Interleukin 18 together with interleukin 12 inhibits IgE production by induction of interferon-g production from activated B cells. Proc. Natl Acad. Sci. USA94, 3948–3953 (1997).
   PubMed Web of Science ®Google Scholar
• Thibodeaux DK, Hunter SE, Waldburger KE et al. Autocrine regulation of IL-12 receptor expression is independent of secondary IFN-γ secretion and not restricted to T and NK cells. J. Immunol.163(10), 5257–5264 (1999).
   PubMed Web of Science ®Google Scholar
• Skok J, Poudrier J, Gray D. Dendritic cell-derived IL-12 promotes B cell induction of Th2 differentiation: a feedback regulation of Th1 development. J. Immunol.163(8), 4284–4291 (1999).
   PubMed Web of Science ®Google Scholar
• Arulanandam BP, O’Toole M, Metzger DW. Intranasal interleukin-12 is a powerful adjuvant for protective mucosal immunity. J. Infect. Dis.180(4), 940–949 (1999).
   PubMed Web of Science ®Google Scholar
• Arulanandam BP, Lynch JM, Briles DE, Hollingshead S, Metzger DW. Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection. Infect. Immun.69(11), 6718–6724 (2001).
   PubMed Web of Science ®Google Scholar
• Lynch JM, Briles DE, Metzger DW. Increased protection against pneumococcal disease by mucosal administration of conjugate vaccine plus interleukin-12. Infect. Immun.71(8), 4780–4788 (2003).
   PubMed Web of Science ®Google Scholar
• Sun K, Johansen FE, Eckmann L, Metzger DW. An important role for polymeric Ig receptor-mediated transport of IgA in protection against Streptococcus pneumoniae nasopharyngeal carriage. J. Immunol.173(7), 4576–4581 (2004).
   PubMed Web of Science ®Google Scholar
• Baron SD, Singh R, Metzger DW. Inactivated Francisella tularensis live vaccine strain protects against respiratory tularemia by intranasal vaccination in an IgA-dependent fashion. Infect. Immun.75(5), 2152–2162 (2007).
   PubMed Web of Science ®Google Scholar
• Arulanandam BP, Metzger DW. Modulation of mucosal and systemic immunity by intranasal interleukin 12 delivery. Vaccine17(3), 252–260 (1999).
   PubMed Web of Science ®Google Scholar
• Buchanan RM, Arulanandam BP, Metzger DW. IL-12 enhances antibody responses to T-independent polysaccharide vaccines in the absence of T and NK cells. J. Immunol.161(10), 5525–5533 (1998).
   PubMed Web of Science ®Google Scholar
• Metzger DW, McNutt RM, Collins JT et al. Interleukin-12 acts as an adjuvant for humoral immunity through interferon-g-dependent and -independent mechanisms. Eur. J. Immunol.27(8), 1958–1965 (1997).
   PubMed Web of Science ®Google Scholar
• Huber VC, Lynch JM, Bucher DJ, Le J, Metzger DW. Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J. Immunol.166(12), 7381–7388 (2001).
   PubMed Web of Science ®Google Scholar
• Arulanandam BP, Lynch JM, Briles DE, Hollingshead S, Metzger DW. Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection. Infect. Immun.69(11), 6718–6724 (2001).
   PubMed Web of Science ®Google Scholar
• Buchanan RM, Briles DE, Arulanandam BP et al. IL-12-mediated increases in protection elicited by pneumococcal and meningococcal conjugate vaccines. Vaccine19(15–16), 2020–2028 (2001).
   PubMed Web of Science ®Google Scholar
• Andersson Å, Dai WJ, Di Santo JP, Brombacher F. Early IFN-γ production and innate immunity during Listeria monocytogenes infection in the absence of NK cells. J. Immunol.161(10), 5600–5606 (1998).
   PubMed Web of Science ®Google Scholar
• Hedlund J, Langer B, Konradsen HB, Ortqvist A. Negligible adjuvant effect for antibody responses and frequent adverse events associated with IL-12 treatment in humans vaccinated with pneumococcal polysaccharide. Vaccine20(1–2), 164–169 (2001).
   PubMed Web of Science ®Google Scholar
• Huber VC, Arulanandam BP, Arnaboldi PM et al. Delivery of IL-12 intranasally leads to reduced IL-12-mediated toxicity. Int. Immunopharmacol.3(6), 801–809 (2003).
   PubMed Web of Science ®Google Scholar